Business
Intensity Therapeutics' INT230-6 Demonstrates Increased Survival as Either Monotherapy or in Combination with Pembrolizumab in Patients with Relapsed, Refractory, Metastatic Solid Tumor Cancers
Patients Receiving INT230-6 Alone (n=64) had a Median Overall Survival (mOS) of 373 Days Data Show INT230-6 is Well Tolerated and Elicits Both Direct Tumor
About this update from Intensity Therapeutics, Inc.
[{"type":"text","content":"Patients Receiving INT230-6 Alone (n=64) had a Median Overall Survival (mOS) of 373 Days\nData Show INT230-6 is Well Tolerated and Elicits Both Direct Tumor Killing and Immune Activating Effects in a Variety of Solid Tumors\nCombined with Pembrolizumab in a Population Consisting of Heavily Pretreated Patients with Primarily Pancreatic, Bile Duct, Colorectal, and Triple Negative Breast Cancer (n=24), Whose Cancer Progressed, the mOS was 205 Days \nFull Set of Results to be Presented at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting\nWESTPORT, Conn., Nov. 11, 2022 /PRNewswire/ -- Intensity Therapeutics, Inc. (\"Intensity\"), a clinical-stage biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral therapies designed to kill tumors and increase immune system recognition of cancers, announced that data from its ongoing phase 1/2 clinical trial demonstrating the efficacy and tolerability of INT230-6, either as monotherapy or in combination with pembrolizumab in patients with relapsed, refractory and metastatic solid tumors, will be presented today at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting being held in Boston and virtually November 8-12, 2022.\nAbstract Number: 710Title: Safety and Survival Results From a Phase 1/2 Trial of Intratumoral Agent INT230-6 (cisplatin vinblastine) Induces Immunological Cancer Cell Death Alone or With Pembrolizumab in Patients with Refractory, Metastatic CancersFirst Author: Jacob Stephen Thomas, M.D.Session Date and Time: Friday, November 11, 2022, 9:00 am - 9:00 pm ESTLocation: Boston Convention Center Hall C; In-Person & On Demand\nCopies of the presentation materials will be available on the Intensity Therapeutics website on the publications and posters page.\n\"Despite significant innovation in immunotherapeutic and checkpoint inhibitor therapy approaches for cancer treatment, patients with metastatic and refractory disease continue to have poor survival and response rates remain low in many tumor types,\" stated Jacob S. Thomas, M.D., Assistant Professor of Clinical Medicine, Keck School of Medicine of USC at the University of Southern California (USC) and an oncologist at USC's Norris Comprehensive Cancer Center, part of Keck Medicine of USC. \"The active drug agents of INT230-6 remain in the tumor f...